Development asset linked to SWEDISH ORPHAN BIOVITRUM in public FDA and regional records.
pharma · Nicotine use
SWEDISH ORPHAN BIOVITRUM
Swedish Orphan Biovitrum Pty Ltd
SWEDISH ORPHAN BIOVITRUM drug portfolio — 10 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
IT HQ
3 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- IT
- Employees
- 3
- Programs
- 2
- Drugs
- 10
- Patents
- 0
SWEDISH ORPHAN BIOVITRUM pipeline
Portfolio lens on 10 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
SWEDISH ORPHAN BIOVITRUM drug portfolio — 10 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
anakinra
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Interleukin-1 receptor type 1.
- Target
- Interleukin-1 receptor type 1
- Mechanism
- Interleukin-1 receptor antagonist
-
avatrombopag
Blood and blood forming organs (B02)Blood and blood forming organs (B02) compound in SWEDISH ORPHAN BIOVITRUM's portfolio. Molecular target: Thrombopoietin receptor.
- Target
- Thrombopoietin receptor
- Mechanism
- Thrombopoietin receptor agonist
-
US regulatory status: approved. Mechanism: Dihydrofolate reductase inhibitor.
- Mechanism
- Dihydrofolate reductase inhibitor
-
Development asset linked to SWEDISH ORPHAN BIOVITRUM in public FDA and regional records.
-
emapalumab
Antineoplastic and immunomodulating agents (L04)Antineoplastic and immunomodulating agents (L04) compound in SWEDISH ORPHAN BIOVITRUM's portfolio. Molecular target: Interferon gamma.
- Target
- Interferon gamma
- Mechanism
- Interferon gamma inhibitor
-
Development asset linked to SWEDISH ORPHAN BIOVITRUM in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Neuronal acetylcholine receptor; alpha4/beta2.
- Target
- Neuronal acetylcholine receptor; alpha4/beta2
- Mechanism
- Neuronal acetylcholine receptor; alpha4/beta2 agonist
-
US regulatory status: approved. Molecular target: Neuronal acetylcholine receptor; alpha4/beta2.
- Target
- Neuronal acetylcholine receptor; alpha4/beta2
- Mechanism
- Neuronal acetylcholine receptor; alpha4/beta2 agonist
-
pegcetacoplan
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Complement C3.
- Target
- Complement C3
- Mechanism
- Complement C3 inhibitor